Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to make pain relief safer after abdominal surgery

NCT ID NCT07581275

Knowledge-focused Sponsor: University of Liege Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how the numbing drug levobupivacaine behaves in the blood after a TAP block, a common pain relief procedure for abdominal surgery. Researchers will take blood samples from 26 adult patients over three hours to measure drug levels. The goal is to find a safe time window to give another painkiller, lidocaine, through an IV without risking side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
levobupivacaine
What this could lead to
If successful, this could help doctors safely combine TAP blocks with IV lidocaine for better pain control after abdominal surgery.
What could go wrong
This is a small, early observational study with only 26 participants. It does not test any new treatment, so it may not lead to immediate changes in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 26 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients treated at CHU Liège who are scheduled for elective abdominal surgery under general anesthesia and for whom an ultrasound-guided transversus abdominis plane (TAP) block with levobupivacaine is planned as part of routine perioperative analgesic care. The study population consists of clinically stable surgical patients able to provide informed consent and undergo serial perioperative blood sampling for pharmacokinetic analysis.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Scheduled elective abdominal surgery under general anesthesia * Planned ultrasound-guided TAP block as part of standard perioperative analgesic care * Able to understand and speak French sufficiently to understand the study information and consent form * Able and willing to provide written informed consent Exclusion Criteria: * Refusal or inability to provide informed consent * Known allergy or hypersensitivity to amide local anesthetics * Severe hepatic impairment * Renal impairment (estimated glomerular filtration rate \<50 mL/min/1.73 m²) * Contraindication to repeated blood sampling or inability to complete the sampling schedule * Participation in another clinical study that could affect absorption, distribution, metabolism, or elimination of local anesthetics * Pregnancy * Emergency surgery or life-threatening urgent condition * Immediate postoperative instability requiring intensive care transfer (e.g., hemodynamic instability) * Inability to understand French sufficiently for study information and consent * Persons requiring special legal protection for consent (e.g., minors, guardianship, incapacity to consent)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Abdominal surgery patients are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Bites and Stings local anesthetic poisoning

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Abdominal surgery patients Levobupivacaine Local anaesthetic systemic toxicity Pharmacokinetic analysis Transversus abdominis plane (TAP) block

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.